Skip to main content

TELA Bio, Inc.

For the period ended Dec 31, 2024. Filed Mar 21, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 21, 2025

TELA$0.86+5.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​​​
​TELA BIO, INC.
​​​
​By:/s/ ANTONY KOBLISH
​​Name: Antony Koblish
​​Title: President, Chief Executive Officer and DirectorDate: March 21, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
​​​​​
/s/ ANTONY KOBLISH​President, Chief Executive Officer and Director (Principal Executive Officer)​March 21, 2025
Antony Koblish​​
​​​​​
/s/ ROBERTO CUCA​Chief Operating Officer and Chief Financial Officer(Principal Financial Officer)​March 21, 2025
Roberto Cuca​​
​​​​​
/s/ MEGAN SMEYKAL​Chief Accounting Officer and Controller (Principal Accounting Officer)​March 21, 2025
Megan Smeykal​​
​​​​​
/s/ DOUG EVANS​Chairman, Board of Directors​March 21, 2025
Doug Evans​​​​
​​​​​
/s/ KURT AZARBARZIN​Director​March 21, 2025
Kurt Azarbarzin​​​​
​​​​​
/s/ JEFFREY BLIZARD​Director​March 21, 2025
Jeffrey Blizard​​​​
​​​​​
/s/ VINCE BURGESS​Director​March 21, 2025
Vince Burgess​​​​
​​​​​
/s/ LISA COLLERAN​Director​March 21, 2025
Lisa Colleran​​​​
​​​​​
/s/ FEDERICA O’BRIEN​Director​March 21, 2025
Federica O’Brien​​​​
​​​​​
​​​​​
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.